NCT06963710 - A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

August 31, 2028

Conditions

Chronic Hepatitis B Infection

Interventions

DRUG

ALG-000184

300 mg tablet

DRUG

TDF

300 mg tablet

Trial Locations (19)

1142

RECRUITING

Aligos Investigational Site, Auckland

10075

RECRUITING

Aligos Investigational Site, Manhasset

20815

RECRUITING

Aligos Investigational Site, Chevy Chase

33136

RECRUITING

Aligos Investigational Site, Maimi

80756

RECRUITING

Aligos Investigational Site, Kaohsiung City

85224

RECRUITING

Aligos Investigational Site, Chandler

91105

RECRUITING

Aligos Investigational Site, Pasadena

92118

RECRUITING

Aligos Investigational Site, Coronado

92377

RECRUITING

Aligos Investigational Site, Rialto

92840

RECRUITING

Aligos Investigational Site, Garden Grove

95116

RECRUITING

Aligos Investigational Site, San Jose

210003

RECRUITING

Aligos Investigational Site, Nanjing

510515

RECRUITING

Aligos Investigational Site, Guangzhou

Unknown

RECRUITING

Aligos Investigational Site, Vancouver

RECRUITING

Aligos Investigational Site, Hong Kong

MD-2025

RECRUITING

Aligos Investigational Site, Chisinau

G4 0SF

RECRUITING

Aligos Investigational Site, Glasgow

SE5 9RS

RECRUITING

Aligos Investigational Site, London

SW10 9NH

RECRUITING

Aligos Investigational Site, London